A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

NCT05593666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Primary Visceral Leishmaniasis

Interventions

DRUG: LXE408
OTHER: Placebo
DRUG: AmBisome®

Sponsor

Drugs for Neglected Diseases

Collaborators

[object Object]